Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – Here’s What Happened

Cel-Sci Corporation (NYSEAMERICAN:CVM) traded down 6.5% during mid-day trading on Friday . The stock traded as low as $5.44 and last traded at $5.48. 58,410 shares changed hands during mid-day trading, a decline of 11% from the average session volume of 65,541 shares. The stock had previously closed at $5.86.

Cel-Sci Price Performance

The firm has a market cap of $46.09 million, a price-to-earnings ratio of -0.56 and a beta of 0.54. The stock has a 50-day moving average price of $6.17 and a 200 day moving average price of $7.31. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.26 and a quick ratio of 2.20.

Hedge Funds Weigh In On Cel-Sci

A number of hedge funds and other institutional investors have recently made changes to their positions in CVM. US Bancorp DE purchased a new stake in Cel-Sci during the 3rd quarter valued at approximately $80,000. MAI Capital Management grew its stake in shares of Cel-Sci by 18.4% in the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock valued at $707,000 after purchasing an additional 11,928 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Cel-Sci by 59.7% in the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after purchasing an additional 109,352 shares during the period. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.